Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 187 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo to Methotrexate Clear all
Completed Phase 3 Interventional Results available

A Study in Moderate to Severe Rheumatoid Arthritis

NCT01710358
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Baricitinib, Methotrexate, Adalimumab Placebo, Baricitinib Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
45
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 30, 2026, 2:39 PM EDT
Completed No phase listed Observational Results available

PET/CT Imaging Companion Study To ACTG A5314

NCT02312219
View directory record Official record
Conditions
HIV, Inflammation, Atherosclerosis
Interventions
Folic Acid, Placebo, Low Dose Methotrexate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional Results available

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

NCT02862574
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Andecaliximab, Placebo, Methotrexate, TNF Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

NCT01709578
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
56
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

NCT00458146
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MM-093
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
20
States / cities
Montgomery, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 4 Interventional Results available

Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis

NCT00195494
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Methotrexate, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

NCT00628095
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CE-224,535, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Mesa, Arizona • DeBary, Florida • Lake Mary, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

NCT00847613
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Huntsville, Alabama • Tucson, Arizona • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

NCT01711359
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Baricitinib, Methotrexate, Baricitinib Placebo, MTX Placebo, Folic Acid
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
47
States / cities
Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00264550
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab 100 mg, Golimumab 50 mg, Methotrexate, Placebo injection, Placebo capsules
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
13
States / cities
Mobile, Alabama • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

NCT02043587
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
Interventions
DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 1 Interventional

Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate

NCT01329991
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PLX5622, Placebo
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Anniston, Alabama • Lansing, Michigan • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis

NCT00579878
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate-Sulfasalazine-Hydroxychloroquine, Leflunomide-Sulfasalazine-Hydroxychloroquine
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

NCT00106535
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Placebo, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
61
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

NCT01359943
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
secukinumab (AIN457), placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT01862224
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
JNJ-38518168, Placebo, Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

NCT00853385
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo, Biologic TNFi
Drug · Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
38
States / cities
Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

NCT01554696
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
peficitinib, Placebo, methotrexate
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Huntington Beach, California • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

NCT01976364
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Tofacitinib, Methotrexate, Placebo Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

NCT00810199
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], methotrexate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
21
States / cities
Santa Monica, California • Upland, California • Whittier, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00535782
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
26
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

NCT00976599
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 + methotrexate, Placebo + Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Frederick, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

NCT01185353
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
LY3009104, Placebo, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
31
States / cities
Paradise Valley, Arizona • Peoria, Arizona • Covina, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

NCT02969044
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Northridge, California • St Louis, Missouri • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 30, 2026, 2:39 PM EDT